ERBB2 and carcinosarcoma: As HER2 positivity was recommended to be defined as 2+ and 3+ scores on protein expression for gynecologic carcinosarcomas, only two patients (two of 11, 18.2%) met the criteria, which is significantly lower than what was reported in UCS while remarkably higher than that in serous ovarian carcinoma (9).